Actelion Hikes Dividend, Opsumit Approval Awaited

14.02.2013 - Swiss group Actelion has raised its dividend 25% as it awaits a U.S. regulatory decision on a new heart and lung drug it hopes will cut its dependency on current mainstay Tracleer...